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OBJECTIVE—In the French Data from the Epidemiological Study on the Insulin Resistance
Syndrome (DESIR) cohort, cross-sectional analyses have shown that a higher consumption of
dairy products and calcium are associated with a lower prevalence of the metabolic syndrome
(MetS). We assess the inﬂuence of dairy products on 9-year incident MetS and on impaired
fasting glycemia and/or type 2 diabetes (IFG/T2D).
RESEARCH DESIGN AND METHODS—Men and women who completed a food fre-
quency questionnaire at baseline and after 3 years were studied (n = 3,435). Logistic regression
models were used to study associations between the average year 0 and year 3 consumption of
milk and dairy products, cheese, dietary calcium density, and incident MetS and IFG/T2D after
adjustingfor1)sex,age,alcohol,smoking,physicalactivity,fatintakeand2)additionallyforBMI.
Associations between dairy products and continuous variables were studied by repeated-measures
ANCOVA, using the same covariates.
RESULTS—Dairy products other than cheese, and dietary calcium density, were inversely
associated with incident MetS and IFG/T2D; cheese was negatively associated with incident
MetS. All three parameters were associated with lower diastolic blood pressure, and with a lower
BMIgain.Highercheeseintakeandcalciumdensitywereassociatedwithalowerincreaseinwaist
circumference and lower triglyceride levels. Calcium density was also associated with a lower
systolic blood pressure and a lower 9-year increase in plasma triglyceride levels.
CONCLUSIONS—A higher consumption of dairy products and calcium was associated with a
lower 9-year incidence of MetS and IFG/T2D in a large cohort drawn from the general population.
Diabetes Care 34:813–817, 2011
T
h em e t a b o l i cs y n d r o m e( M e t S )i sa
cluster of metabolic disorders, includ-
ingcentralobesity,glucoseintolerance
(impaired fasting glucose [IFG], impaired
glucose tolerance, type 2 diabetes), dys-
lipidemia(lowHDLcholesterol[HDL-C],
high triglyceride levels), and high blood
pressure. All of its components are risk
factors for cardiovascular disease (CVD).
Althoughfatsfromdairyproductsarerich
in saturated fatty acids, there is no clear
evidence that dairy food is associated
with a high risk of CVD (1). An explana-
tion is that dairy consumption has been
found to be inversely associated with
MetS traits in cross-sectional as well as
prospective studies. In the French popu-
lation from the Data from the Epidemio-
logical Study on the Insulin Resistance
Syndrome (DESIR) cohort, cross-sectional
analyses have shown that a higher con-
sumption of dairy products or calcium
was associated with a lower prevalence of
theMetS(2,3).IntheCoronaryArteryRisk
Development in Young Adults (CARDIA)
study, the highest consumption of dairy
products was associated with a 70% re-
ductionintherisk ofincidentMetSovera
period of 10 years, when compared with
the group with the lowest consumption
(4). However, these results were not al-
ways found. In an elderly Dutch popula-
tionfromtheHoornStudywitha6.4-year
follow-up, a higher dairy consumption
did not protect against weight gain or
thedevelopmentofmetabolicdisturbances
(5). The aim of our study was to assess the
inﬂuence of dairy products on the 9-year
cumulative incidence of the MetS and
IFG and/or type 2 diabetes (IFG/T2D) as
well as on associated traits, in the French
population-based prospective study with a
9-year follow-up, DESIR.
RESEARCH DESIGN AND
METHODS—The DESIR study is a
prospective study of 5,212 subjects at
inclusion (2,576 men and 2,636 women,
aged 30–65 years), recruited from volun-
teerswhowereofferedperiodichealthex-
aminations free of charge by the French
Social Security system in 10 health exam-
ination centers from the western part of
France. They were clinically and biologi-
cally evaluated at visits every 3 years, and
the ﬁnal examination was 9 years after in-
clusion.Forthepurposeoftheseanalyses,
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ORIGINAL ARTICLEdiabetic subjects at entry were excluded.
In addition, subjects who declared that
they were on a diet and those who did
not answer all the questions in the food
frequency questionnaire were excluded.
In consequence, the 3,435 subjects
(1,710 men, 1,725 women) with a food
frequency questionnaire at baseline and/or
at 3 years remained for this study. The
studywasapprovedbytheethicscommit-
tee of the Kremlin Bicêtre Hospital,and all
participants signed an informed consent.
Measurements
Weight, height, and waist circumferences
were measured by trained personnel.
Venous blood samples were collected in
the morning after subjects had fasted for
12 h. Systolic and diastolic arterial pres-
sures were measured with a mercury
sphygmomanometer adapted for arm
size after 5 min of rest with participants
in a supine position. Two measures of
bloodpressureweretaken,andmeanswere
used for the analysis. A detailed description
of laboratory measurements including fast-
i n gt r i g l y c e r i d e s ,H D L - C ,g l u c o s e ,a n di n -
sulin is provided elsewhere (6).
In the present work, two deﬁnitions
for the MetS were used. According to the
International Diabetes Federation (7), it
was deﬁned as waist circumference
$94/80 cm for men/women plus two of
the following factors: 1) elevated triglyc-
erides: $1.70 mmol/L or speciﬁct r e a t -
ment for this lipid abnormality; 2)
reduced HDL-C: #1.03 mmol/L for men
and 1.29 mmol/L for women or speciﬁc
treatment for this lipid abnormality; 3)
elevated blood pressure: $ 130/85
mmHg or treatment of previously diag-
nosed hypertension; and 4) elevated fast-
ing glycemia $ 5.6 mmol/l or previously
diagnosed type 2 diabetes (treated by glu-
cose lowering drugs and/or fasting gly-
cemia $ 7.0 mmol/l). According to the
National Cholesterol Education Program-
Adult Treatment Panel III (8), it was de-
ﬁned as three of the following factors:
1) waist circumference .102/88 cm for
men/women; 2) elevated triglycerides:
$1.70 mmol/L; 3) reduced HDL-C:
#1.03 mmol/L for men and 1.29 mmol/L
for women; 4) elevated blood pressure:
systolicbloodpressure$130ordiastolic
$ 85 mmHg; and 5) elevated fasting gly-
cemia $6.1 mmol/L.
Type2diabeteswasdeﬁnedasfasting
plasma glucose $7 mmol/L or treatment
byantidiabeticagents. IFGwas deﬁnedas
fasting plasma glucose between 6.1 and
6.9 mmol/L. Incident cases for MetS
and/or IFG/T2D were deﬁned as sub-
jects free of disease at entry who devel-
oped the disease at any time during the
follow-up.
A 23-item questionnaire was com-
pleted by each participant to determine
thefrequencyandlevelofconsumptionof
different foods. This questionnaire has
been validated by comparison with the
dietary history method consisting of 30-
min interviews by trained dietitians. This
validation study enabled the determina-
tion of multiple linear regression equa-
tions to estimate the main nutrient
intakes (including calcium) from the
questions on the consumption of differ-
ent foods (9). Two groups of dairy prod-
ucts were deﬁned: cheese or milk and
other dairy products (except cheese).
One portion was deﬁned as 30 g for
cheese, and 125 mL for milk or milk
products. There were four responses for
the intake of dairy products (never; , 1
portion/day; 1–2/ d a y ;. 2 /day; coded
1,2,3,4) and 3 for cheese intake (0–1
portion/day; 2–3/ d a y ;. 3/day; coded
1,2,3). Calcium density of the diet was de-
ﬁnedastheamountofcalciumingestedper
1,000 kCal (excluding alcohol).
Statistics
Analyses used the average dietary data
from year 0 and year 3 to take into
account the variability over time; 212
participants with only one dietary record
were also included; their exclusion did
notchangetheresults.Wecategorizedthe
dairy intake and the cheese intake in 4
groups and 3 groups, respectively, ac-
cording to their responses to both ques-
tionnaires. The dairy intake groups were
deﬁned as group 1 for an average re-
sponse #2 ,g r o u p2f o ra na v e r a g er e -
sponse of 2.5, group 3 for an average
response of 3, and group 4 for an average
response .3. The cheese intake groups
were deﬁned as group 1 for an average
response of 1, group 2 for an average re-
sponse of 1.5, and group 3 for an average
response $2.These limitswere chosenin
order to have comparable frequencies in
the groups. For calcium, we calculated
sex-speciﬁc quartiles of the mean calcium
density at year 0 and year 3 (3). Multiple
logistic regression analysis was used to
evaluate associations between the dairy
consumption variables, and the odds of
developing MetS or IFG/T2D during the
9-year study. Two models were used: in
model 1, the covariates were age, sex, alco-
hol consumption (continuous covariate),
smoking (yes/no), physical activity (three
classes used as a continuous covariate), fat
intake (from the questions on the con-
sumption of meat, ﬁsh, pork products,
fried foods, butter, cheese, and other dairy
products); in model 2, the same covariates
as well as BMI as a covariate. To take into
account the variation in BMI over the
9 years, we used as covariate the mean of
BMI at entry and at 9 years. Odds ratios
indicate the risk of a change from one cat-
egory to the next, e.g., from one quartile
of calcium density to the next quartile.
ANCOVA with repeated measures was
used to test for the average effect of dairy
products and the effects on changes be-
tween baseline and the end of the follow-
up(9years),adjustedforage,sex,alcohol,
smoking, physical activity, fat intake, and
BMI. Data were log transformed for
skewedvariables(insulinlevels,serumtri-
glycerides). Results are presented as least
squaresmeansadjustedforcovariateswith
the SEM, or as geometric means with 95%
CI for skewed variables.
RESULTS—The consumption of dairy
products other than cheese and the cal-
cium density of the diet were inversely
associated with theincidenceof theMetS,
whatever the deﬁnition, and with the
incidence of IFG/T2D during the 9-year
follow-up (Table 1). The consumption of
cheese was negatively associated with the
incidence of the MetS (Table 1). The con-
sumption of dairy products other than
cheese was associated with the incidence
of type 2 diabetes alone (multiple adjust-
ment without BMI, model 1: odds ratio
0.82 [95%CI 0.71–0.92]; P = 0.02), but
this association was no longer signiﬁcant
after taking BMI into account (model 2,
P = 0.07). Neither cheese nor calcium
density were associated with type 2 dia-
betes alone (data not shown). No interac-
tion with sex was observed nor with
overweight at baseline.
The three dairy parameters were as-
sociatedwith lower 9-yeardiastolicblood
pressure and with lower BMI gain over
this period (Supplementary Table A1–3).
Higher cheese intake and calcium density
were associated with lower triglyceride
levels and a lower 9-year increase in waist
c i r c u m f e r e n c eb o t hi nm e na n dw o m e n
(Supplementary Tables A2 and 3). Cal-
cium density was also associated with a
lower systolic blood pressure and a lower
9-y increase in plasma triglycerides levels
(Supplementary Table A3). Few signiﬁ-
cant interaction effects with sex were ob-
served: time changes in systolic blood
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Dairy consumption, hyperglycemia, and metabolic syndromepressure for dairy intake (Supplementary
Table A1), and insulin levels for calcium
density(SupplementaryTableA3),which
weresigniﬁcantonlyinwomen.Somead-
verse effects were observed. Intake of
dairy products was associated with lower
HDL-C levels in men, but the decrease
with time was also lower.Intakeof cheese
was associated witha higher average BMI,
but also with a lower increase with time.
CONCLUSIONS—In the DESIR pro-
spectivestudywitha9-yearfollow-up,we
found that the consumption of dairy
products and cheese as well as dietary
calcium density, were associated with a
lower incidence of the MetS. The con-
sumption of dairy products, cheese ex-
cluded, and calcium intake, were also
associated with a lower incidence of IFG
or type 2 diabetes. When looking at
phenotypes associated with the MetS,
these parameters were also generally as-
sociated with a more beneﬁcial proﬁle
during the follow-up, or with a better
change in proﬁle over the 9-year period.
These results support the hypothesis of
beneﬁcial effects of milk products on
cardiovascular risk, despite their satu-
rated fat content. In a meta-analysis of
prospective studies (10), it was shown
that milk and dairy consumption was as-
sociated with a lower risk of incident vas-
cular events. This might be explained by
beneﬁcial associations with the MetS and
associated parameters and/or type 2 dia-
betes, such as those found in the current
studyandbyothergroups.Inthisrespect,
Warensjö et al. (11) found, in a prospec-
tive study, a negative association between
the risk of myocardial infarction and bio-
markers of milk fat, which disappeared
when adjusted for variables related to
the MetS (diabetes, blood pressure, BMI).
Our results are consistent with those
obtained in the prospective Atherosclero-
sis Risk in Communities (ARIC) study
(12)wheresubjectsinthehighestquintile
of dairy consumption had a 13% lower
risk of the MetS when compared with
the lowest quintile. In another prospec-
tive study, CARDIA (4), results were sim-
ilar, but only in the overweight. As stated
in the paper by Lutsey et al. (12), the dif-
ferences between studies may be the re-
sult of different methods used, for
example deﬁnition of outcome, popula-
tion, age, dietary assessment, and statisti-
cal methods. Both the DESIR and the
ARIC studies were in the middle-aged,
but the CARDIA study was in young
adults, aged 18–30 years.
In prospective studies, for men with a
12-year follow-up (13), as in women
with a 10-year follow-up (14), there
was a negative association between dairy
intake and type 2 diabetes incidence. In
these two studies, the association with
dairywasmainlyduetolow-fatdairy.Un-
fortunately, we do not have speciﬁcd a t a
on low-fat or high-fat dairy products in
our study, but we believe that our results
are in accordance with this differential
effect as dairy products included milk
w h i c hi sc o n s u m e da s8 0 %l o w - f a ta n d
are associated beneﬁcially with IFG/
T2D, whereas cheese, which is high-fat,
is not signiﬁcantly associated with IFG/
T2D risk. In the Nurses Health Study
(15), women who consumed three or
more servings per day had an 11% lower
risk of type 2 diabetes compared with
women who consumed less than one
serving per day of dairy. After adjustment
for total vitamin D and calcium intake,
this association was attenuated, showing
that the association with dairy food was
due in large part to these nutrients. In
DESIR study, the calcium density of the
diet was also very signiﬁcantly associated
Table 1—Incidence of the MetS and IFG/T2D according to dairy product consumption in the DESIR cohort
No incident
MetS (IDF)
Incident
MetS (IDF)
No incident
MetS (NCEP)
Incident
MetS (NCEP)
No incident
IFG/T2D
Incident
IFG/T2D
Dairy products (except cheese)
Group 1 (low) 430 (69.2) 191 (30.8) 568 (81.5) 129 (18.5) 543 (77.5) 158 (22.5)
Group 2 423 (75.3) 139 (24.7) 525 (84.1) 99 (15.9) 522 (83.8) 101 (16.2)
Group 3 960 (81.4) 220 (18.6) 1,111 (87.3) 162 (12.7) 1,126 (87.0) 169 (13.1)
Group 4 (high) 525 (81.8) 117 (18.2) 608 (90.7) 62 (9.3) 607 (89.1) 74 (10.9)
Unadjusted 0.77 (0.71–0.84); P , 10
26 0.78 (0.70–0.85); P , 10
26 0.74 (0.68–0.81); P , 10
26
Model 1† 0.86 (0.79–0.94); P = 0.001 0.84 (0.76–0.93); P = 0.0007 0.83 (0.75–0.92); P = 0.0003
Model 2‡ 0.88 (0.79–0.97); P = 0.01 0.89 (0.79–1.00); P = 0.04 0.85 (0.76–0.94); P =0 . 0 0 1
Cheese
Group 1 (low) 718 (76.7) 218 (23.3) 847 (85.2) 147 (14.8) 868 (85.5) 147 (14.5)
Group 2 (medium) 511 (76.5) 157 (23.5) 636 (86.2) 102 (13.8) 639 (85.7) 107 (14.3)
Group 3 (high) 1,109 (79.2) 292 (20.8) 1,329 (86.7) 203 (13.3) 1,291 (83.9) 248 (16.1)
Unadjusted 0.93 (0.84–1.02); P = 0.14 0.94 (0.84–1.05); P =0 . 2 8 1 . 0 7( 0 . 9 6 –1.19); P =0 . 2 3
Model 1† 0.90 (0.80–1.00); P = 0.06 0.86 (0.76–0.98); P =0 . 0 2 0 . 9 4( 0 . 8 3 –1.07); P =0 . 3 7
Model 2‡ 0.88 (0.77–1.00); P =0 . 0 5 0 . 8 2( 0 . 7 1 –0.95); P = 0.008 0.93 (0.82–1.06); P =0 . 3 0
Calcium density
Quartile 1 553 (74.6) 188 (25.4) 668 (82.8) 139 (17.2) 676 (81.8) 150 (18.2)
Quartile 2 576 (75.7) 185 (24.3) 716 (86.6) 111 (13.4) 709 (84.3) 132 (15.7)
Quartile 3 601 (79.7) 153 (20.3) 707 (85.0) 125 (15.0) 696 (84.6) 127 (15.4)
Quartile 4 608 (81.2) 141 (18.8) 721 (90.4) 77 (9.6) 717 (88.5) 93 (11.5)
Unadjusted 0.87 (0.81–0.94); P =0 . 0 0 0 5 0 . 8 4( 0 . 7 7 –0.92); P = 0.0001 0.85 (0.78–0.93); P = 0.0003
Model 1† 0.90 (0.82–0.97); P = 0.009 0.86 (0.78–0.94); P = 0.001 0.91 (0.83–1.00); P =0 . 0 5
Model 2‡ 0.86 (0.78–0.95); P = 0.002 0.83 (0.75–0.92); P = 0.001 0.90 (0.82–0.99); P =0 . 0 4
Dataaren(%)oroddsratio(95%CI)unlessotherwiseindicated.Oddsratioswerecalculatedbylogisticregressionandindicatetheriskforachangefromonecategory
to the next. IDF, International Diabetes Federation; NCEP, National Cholesterol Education Program. †Model 1: adjustment for sex, age, smoking, total fat intake,
physical activity. ‡Model 2: same as model 1 plus adjustment for mean BMI (mean of BMI at baseline and at 9 years of follow-up).
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Fumeron and Associateswith IFG/T2D and the MetS, but since it
was not directlymeasuredbutonly calcu-
lated from food intake mainly from dairy
variables (therefore very linked to the as-
sessment of dairy intake), we could not
adjust for this variable in order to test
whether the beneﬁcial effects of dairy
were due to calcium in DESIR. Unfortu-
nately, we do not have data on vitamin D.
Compounds other than calcium and vita-
min D may be involved in these associa-
tions: peptides or conjugates of linoleic
acid (1,16,17).
Dairy consumption and calcium in-
take have been described in epidemiolog-
ical studies to be associated with lower
BMI or to lower body weight in interven-
tion studies, in humans as well as in
animal models (18,19). In our longitudi-
nal study, we did not ﬁnd an overall as-
sociation with BMI, but there was a lower
increase in BMI and/or waist circumfer-
ence over the 9-year follow-up. A similar
ﬁnding was found in the CARDIA study
(4), in which high dairy intake appeared
toprotectagainstweightgain.Incontrast,
this result was not found in the Hoorn
Study(5).IntheFrenchSupplementation
en Vitamines et Mineraux Antioxydants
(SU.VI.MAX) study, a high consumption
of dairy products was associated with a
lower weight gain over 6 years, but this
result was obtained only in overweight
men (20). In the DESIR study, no signif-
icant interaction with sex was found for
BMI changes, but we observed a signiﬁ-
cantly lower BMI increase only in men
(P = 0.07, 0.05, and 0.002 for dairy prod-
ucts, cheese, and calcium density respec-
tively).TheeffectsonBMIdidnotexplain
all of the effects on the MetS, as we ad-
justed for BMI in all our analyses.
Modestbutsigniﬁcanteffectsontriglyc-
erides were found. Nevertheless, no ben-
eﬁcialeffectonHDL-Cwasobserved.These
results are very similar to those from the
CARDIA study (4). The adjustments that
we systematically used—BMI, fat intake,
physical activity and alcohol—might have
lessened or cancelled these associations.
Hereweobservedanegativeassociationbe-
tween cheese and triglycerides which has
been found sometimes (21,22), but not al-
ways (23,24), in cross-sectional studies.
Dairy consumption has generally
been associated with low blood pressure.
This was found in the cross-sectional
analysis of the Hoorn Study (24) but not
in the prospective data (5). In our study,
only the mean effect was found to be sig-
niﬁcant, but generally there was no effect
on changes. Dairy nutrients, notably
calcium,havebeenshowntohaveablood
pressure lowering effect. Dairy peptides
may also act as ACE inhibitors (16)
Consistently with the results con-
cerning the MetS and/or IFG/T2D, we
found a negative association between the
calcium density of the diet and insulin
levels. This association, which was de-
tectedonlyinwomen,mightbeexplained
by the higher dietary calcium density in
women than in men (3). A negative trend
was also found with cheese intake (P =
0.07). In acute effect, milk intake has
been associated with higher insulin levels
due to insulin-secretagogue peptides;
nevertheless, its chronic effect has rather
been linked to an improvement in insulin
sensitivity and thus, presumably, with
lower insulinemia. Dairy foods may ben-
eﬁcially alter adiponectin levels indepen-
dently of changes in body weight (18).
This in turn may increaseinsulin sensitiv-
ity and lower insulin levels. It has also
been observed that milk and whey appear
insulinotropic as an acute effect but that
the addition of fermented milk (yogurt)
lowered postprandial insulin and glucose
as compared with a reference meal alone
(17). Moreover, whey protein was associ-
ated with a 40% lower plasma insulin af-
ter 6 weeks in insulin-resistant rats (17).
Biomarkers of milk fat were also nega-
tivelyassociatedwithplasmainsulin(25).
There was no signiﬁcant interaction
between dairy variables and sex on the
risk of the MetS or on IFG/T2D (actually
the results were very similar [data not
shown]), and very few signiﬁcant inter-
actions were observed for associations
with continuous variables.
Our study has several strengths but
also some limitations. Among the
strengths are the prospective nature of
the data and the large number of partic-
ipants included, who were from the gen-
eral population, and selected with a 1:1
sex ratio and in age strata. We were also
able to adjust for confounders such as
lifestyle factors. The relationships we
observed with the characteristics of the
MetS are modest, but they were obtained
after adjustment for lifestyle variables,
including physical activity, smoking, al-
cohol consumption, and dietary fat in-
take. Moreover, the adjustments for BMI
show that there may be a speciﬁci n d e -
pendent effect of dairy intake on the MetS
characteristics.Themainlimitationofour
study concerns the dietary questionnaire.
We used a very simple semiquantitative
self-questionnaire. Nevertheless, it has
been validated by a more sophisticated
questionnaire (9) and is suitably short to
be well answered in an epidemiological
study. As with all food-frequency ques-
tions, the accuracy of the responses
(under- or over-consumption) is difﬁcult
to evaluate. We may have over-evaluated
the consumption of calcium with a semi-
quantitative questionnaire, but the range
of our values is not too far removed from
the range of intake observed in the 1998–
1999 cross-sectional French Enquete
INCA (Individuelle et Nationale sur les
Consommations Alimentaires) food con-
sumption survey (3). We have used the
same food frequency questionnaire, com-
pleted at baseline and at the 3-year visit,
andusingmeanvalueswillreducethevar-
iability of the responses. Our question-
naire does not allow the separation of
low-fat and high-fat products, or to esti-
matetheeffectsofthedifferentdairyprod-
ucts. However, we could separate cheese
from other dairy products. As already
stated, it can be assumed that in France,
cheese is high-fat, but that the milk in-
cluded in other dairy products is low fat.
Insummary,ahigherconsumptionof
dairy products and calcium was associ-
ated with a lower incidence of the MetS
and IFG/T2D during a 9-year follow-up
period, in a large cohort drawn from the
French general population. This inverse
associationwasobservedwithmanytraits
of the MetS. These results indicate that
dairy product consumption could be
associated with a lower cardiovascular
risk.
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